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ABSTRACT 
Objective: To report a case of meropenem induced reduction in serum valproate level.  
Methods: The clinical data of an epileptic patient who experienced a decrease in seizure control due to a drug interaction between valproate and 
meropenem is described.  
Results: The patient was a 26 years old male who was a known case of refractory focal epilepsy and underwent surgery for the same. This patient 
was on five antiepileptic drugs including valproate. On treatment with meropenem for the management of post surgical site infection due to multi-
drug resistant Klebsiella pneumoniae, the patient experienced seizures due to decline in valproate level. Increasing the dose of valproate could not 
control the seizures. However, changing the antibiotics to a non carbapenem controlled the seizures. 
Conclusion: The present report highlights the potential drug interaction between valproate and meropenem. Physicians should thus avoid co-
administration of both these agents. If concomitant administration is essential, close monitoring of valproate concentration and clinical monitoring 
for breakthrough seizures are necessitated. 
Keywords: Meropenem, Carbapenem, Serum valproate, Epilepsy, Drug interaction. 
 
INTRODUCTION 
In patients with epilepsy, drug interactions have proven to be a 
major challenge for the maintenance of therapeutic concentrations 
of antiepileptic drugs. Sodium valproate, one of the most frequently 
used drug in the treatment of generalized tonic-clonic and partial 
seizures, has a narrow therapeutic index [1]. carbapenems like me-
ropenem are considered the drugs of choice for treatment of multi-
drug resistant (MDR) infections including those caused by extended 
spectrum beta-lactamase (ESBL) producing organisms [2-4].  
carbapenem antibiotics, especially meropenem, may decrease the 
plasma concentrations of valproate, thus decreasing its therapeutic 
activity [5-18]. In the present era with increasing incidence of MDR 
bacterial infections, and increasing utilization of carbapenems, this 
drug interaction has significant clinical implications to the patient 
and physician. We report a case of meropenem induced reduction in 
valproate level and discuss the clinical relevance, potential mechan-
isms and management of the valproate carbapenem interaction. 
CASE REPORT 
A 26 years old man, a known case of refractory focal epilepsy was 
admitted to the hospital for left parietal temporal occipital (PTO) 
craniotomy and disconnection under transcranial motor evoked 
potential monitoring. This patient had a history of seizures from 2 
years of age and seizure frequency was 2-3 episodes per day with or 
without generalizations. He was on antiepileptic drugs from child-
hood and on admission was receiving phenobarbital, valproate, 
clobazam, oxcarbazepine and lacosamide. During his stay in the 
hospital, he developed fever and his wound culture grew MDR Kleb-
siella pneumoniae. Hence, the patient was administered meropenem 
500 mg twice daily intravenously, adjusted according to his creati-
nine clearance. The very next day, the patient experienced seizures 
and thus his valproate dosing frequency was increased from 500 mg 
twice daily to thrice daily. But patient did not respond to the in-
crease in the dose of sodium valproate. At this point of time, we 
decided to discontinue meropenem because of the reported poten-
tial for interaction between meropenem and valproate. On the day of 
meropenem discontinuation, the serum valproate level was 21.1 
µg/ml (therapeutic range: 50-100 µg/ml). He was started on non 
carbapenem antibiotic with good response to fever and infection. 
Seizure control was also achieved. After 14 days of discontinuation 
of meropenem serum valproate level was 95.7 µg/ml 
DISCUSSION 
Antiepileptic drugs are commonly prescribed for long periods, to a 
lifetime in most cases. Many patients require treatment with more 
than one AED for optimum control for seizure management of con-
comitant or intercurrent condition, acute or chronic will require 
additional medication. Antimicrobials are the most frequent class of 
drugs co administered for patients on multiple medications. Mecha-
nistically, seizure propensity of the β-lactams is related to their 
binding to γ-amino butyric acid receptors. There are numerous re-
ports of seizure activity associated with imipenem-cilastatin, with 
seizure rates ranging from 3-33%. For meropenem, Doripenem, and 
Ertapenem, the seizure rate for each agent is reported as less than 
1% [19-22].  
Interactions between antiepileptic drugs and antimicrobial agents 
are of prime importance in the management of epilepsy and infec-
tions. Case reports in the literature have shown that co-
administration of carbapenems, including meropenem to patients 
receiving valproate results in a reduction of valproate levels below 
the therapeutic range which impairs seizure control [4]. The exact 
mechanism for this interaction is not known. However, several in 
vitro and animal studies have been carried out in attempts to eluci-
date the mechanisms for carbapenem-valproate interaction. The 
possible mechanisms that have been suggested include inhibition of 
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absorption of valproate at the baso lateral membrane of the intes-
tinal epithelial cells; suppression of entero hepatic circulation, in-
creased uptake of valproate into erythrocytes and inhibition of val-
proate glucuronidase by carbapenem [23-27]. 
Consistent with other reports, in our patient also serum valproate 
levels reduced below therapeutic range following meropenem 
treatment, resulting in seizures. Different studies have reported 
declines in the range of 66% to 90% [11, 28, 29]. However, in the 
present case, the % decline could not be determined due to lack of 
serum valproate concentration prior to initiation of meropenem 
therapy.  
This case confirmed previous literature reports that an increase in 
valproate dose does not compensate for the reduction in serum val-
proate concentration caused by a carbapenem [6, 13]. Seizures were 
controlled only after meropenem treatment was discontinued.  
Haroutiunian et al. [11] have reported gradual increase in valproate 
concentration after 8 to 14 days following discontinuation of mero-
penem. Consistent with the same, in the present case, the serum 
valproate levels 14 days after discontinuation of meropenem thera-
py was within the therapeutic range (95.7 µg/ml).  
Clinically important antiepileptic drug interactions are frequently 
observed in medical practice. Since the therapeutic effect of val-
proate depends on its serum concentration, there may be break-
through seizures control in patients using valproate with carbape-
nem antibiotics due to decline in valproate levels.  
Therefore, physicians should avoid co-administration of both these 
agents. If concomitant administration is essential, adverse clinical 
consequences may be minimized, as appropriate, by individualized 
dose adjustments guided by careful monitoring of clinical response 
and measurement of serum valproate concentrations. 
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